Soin Neuroscience and BIOTRONIK Neuro announce research collaboration for novel SCS waveforms and personalized tuning
Summary
Soin Neuroscience and BIOTRONIK Neuro announced a research collaboration to advance novel stimulation waveforms and personalized spinal cord stimulation tuning algorithms. The collaboration combines Soin Neuroscience's clinical expertise in SCS waveform optimization with BIOTRONIK Neuro's neurostimulation hardware platform. BIOTRONIK — better known for cardiac devices — has been expanding its neurostimulation portfolio through clinical partnerships like this one, seeking differentiated approaches to a market where Medtronic, Abbott, and Boston Scientific dominate standard-of-care SCS.
Why it matters
BIOTRONIK entering SCS waveform innovation through an academic clinical research partnership is the European cardiac device giant's bet on the $3B+ chronic pain SCS market. Novel waveform development is the primary competitive battleground in SCS — where HF10 (Nevro), Burst (Abbott), and Saluda's ECAP-guided approach have each demonstrated superiority over conventional tonic stimulation in specific patient populations. A new waveform partnership could position BIOTRONIK Neuro for genuine SCS market entry.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial